Neurotensin and CRH Interactions Augment Human Mast Cell Activation
Figure 2
NT increases VEGF gene expression and protein secretion in human mast cells, which is blocked by a NTR antagonist.
(A) VEGF mRNA expression was assessed following stimulation of LAD2 cells with NT (1, 2 µM) for 6 h; SP was used as a “positive” control to stimulate mast cell degranulation. (B) VEGF secretion from LAD2 cells was measured after stimulation with NT (1, 2, 10 µM) for 24 h; and (C) VEGF release from LAD2 cells treated for 48 hr with NT (1 µM) and/or followed with CRH (1 µM) for 24 h. The augmentation effect of NT and CRH is blocked by pre-treating with the NT antagonist SR 48692 (10 µM) for 30 min. For all experiments, n = 3; *p<0.05, **p<0.01, ***p<0.001 compared to control.